Absorption and transport of botulinum neurotoxins

Molecular Aspects of Botulinum Neurotoxin

Volumn , Issue , 2014, Pages 35-68

  Popoff, Michel R ^a   Connan, Chloé ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Botulinum complex; Botulinum neurotoxin; Cadherin; Epithelial barrier; Hemagglutinins; Intercellular junctions; Paracellular passage; Receptor mediated transcytosis; Toxin absorption

Indexed keywords

EID: 84955185136     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-9454-6_3     Document Type: Chapter

References (188)

1. Abbruzzese G, Berardelli A (2006) Neurophysiological effects of botulinum toxin type A. Neurotox Res 9:109-114
2. Ahsan CR et al (2005) Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells. J Pharmacol Exp Ther 315:1028-1035
3. Al-Saleem FH et al (2008) The role of systemic handling in the pathophysiologic actions of botulinum toxin. J Pharmacol Exp Ther 326:856-863
4. Al-Saleem FH et al (2012) Analysis of the mechanisms that underlie absorption of botulinum toxin by the inhalation route. Infect Immun 80:4133-4142
5. Antonucci F et al (2008) Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 28:3689-3696
6. Arimitsu H et al (2003) Purification od fully activated Clostridium botulinum serotype B toxin for treatment of patients with dystonia. Infect Immun 71:1599-1603
7. Arimitsu H et al (2008) Molecular properties of each subcomponent in Clostridium botulinum type B haemagglutinin complex. Microb Pathog 45:142-149
8. Arndt JW et al (2005) The structure of the neurotoxin-associated protein HA33/A from Clostridium botulinum suggests a reoccurring beta-trefoil fold in the progenitor toxin complex. J Mol Biol 346:1083-1093
9. Arnon SS (1986) Infant botulism anticipating the second decade. J Infect Dis 154:201-206
10. Arnon SS (1989) Infant botulism. In: Finegold SM, George WL (eds) Anaerobic infections in humans. Academic Press, San Diego, pp 601-609
11. Arnon SS et al (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059-1070
12. Arnon SS (2007) Creation and development of the public service orphan drug Human Botulism Immune Globulin. Pediatrics 119:785-789
13. Ault A (2008) New botulinum toxin injection warnings issued: postinjection symptoms include dysphagia, ptosis andf shortness of breath, according to the FDA. Skin Allergy News 39:13
14. Benefield DA et al (2013) Molecular assembly of botulinum neurotoxin progenitor complexes. Proc Natl Acad Sci U S A 110:5630-5635
15. Bens M et al (1996) Transimmortalized mouse intestinal cells (m-ICc12) that maintain a crypt phenotype. Am J Physiol 270:C1666-1674
16. Bhatia KP et al (1999) Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry 67:90-93
17. Bohnert S, Schiavo G (2005) Tetanus toxin is transported in a novel neuronal compartment characterized by a specialized pH regulation. J Biol Chem 280:42336-42344
18. Bohnert S et al (2006) Uptake and transport of clostridium neurotoxins. In: Alouf JE, Popoff MR (eds) The Sourcebook of comprehensive bacterial protein toxins. Elsevier Academic Press, Amsterdam, pp 390-408
19. Bonventre PF (1979) Absorption of botulinal toxin from the gastrointestinal tract. Rev Infect Dis 1:663-667
20. Breidenbach MA, Brunger AT (2005) 2.3 A crystal structure of tetanus neurotoxin light chain. BioChemistry 44:7450-7457
21. Brook I (2007) Infant botulism. J Perinatol 27:175-180
22. Burr DH, Sugiyama H (1982) Susceptibility to enteric botulinum colonization of antibiotictreated adult mice. Infect Immun 36:103-106
23. Caleo M, Schiavo G (2009) Central effects of tetanus and botulinum neurotoxins. Toxicon 54:593-599
24. Call JE, Cooke PH, Miller AJ (1995) In situ characterization of Clostridium botulinum neurotoxin synthesis and export. J Appl Bacteriol 79:257-263
25. Capaldo CT, Macara IG (2007) Depletion of E-cadherin disrupts establishment but not maintenance of cell junctions in Madin-Darby canine kidney epithelial cells. Mol Biol Cell 18:189-200
26. Carli L, Montecucco C, Rossetto O (2009) Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle Nerve 40:374-380
27. Chadda R et al (2007) Cholesterol-sensitive Cdc42 activation regulates actin polymerization for endocytosis via the GEEC pathway. Traffic 8:702-717
28. Chen F, Kuziemko GM, Stevens RC (1998) Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect Immun 66:2420-2425
29. Chen X, Gumbiner BM (2006) Crosstalk between different adhesion molecules. Curr Opin Cell Biol 18:572-578
30. Chertow DS et al (2006) Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. Jama 296:2476-2479
31. Coban A et al (2010) Iatrogenic botulism after botulinum toxin type A injections. Clin Neuropharmacol 33:158-160
32. Coffield JA et al (1999) Characterization of a vertebrate neuromuscular junction that demonstrates selective resistance to botulinum toxin. J Pharmacol Exp Ther 289:1509-1516
33. Couesnon A, Raffestin S, Popoff MR (2006) Expression of botulinum neurotoxins A and E, and associated non-toxin genes, during the transition phase and stability at high temperature:analysis by quantitative reverse transcription-PCR. Microbiology 152:759-770
34. Couesnon A, Pereira Y, Popoff MR (2008) Receptor-mediated transcytosis of botulinum neurotoxin A through intestinal cell monolayers. Cell Microbiol 10:375-387
35. Couesnon A, Shimizu T, Popoff MR (2009) Differential entry of botulinum neurotoxin A into neuronal and intestinal cells. Cell Microbiol 11:289-308
36. Couesnon A et al (2010) Differential entry of Botulinum neurotoxin A into neuronal and intestinal cells: an ultrastructural approach. Botulinum J 1:375-392
37. Couesnon A et al (2012) Preferential entry of botulinum neurotoxin A Hc domain through intestinal crypt cells and targeting to cholinergic neurons of the mouse intestine. PLoS Pathog 8:e1002583
38. Cox N, Hinkle R (2002) Infant botulism. Am Fam Physician 65:1388-1392
39. Dineen SS, Bradshaw M, Johnson EA (2003) Neurotoxin gene clusters in Clostridium botulinum type A strains: sequence comparison and evolutionary implications. Cur Microbiol 46:342-352
40. Dineen SS et al (2004) Nucleotide sequence and transcriptional analysis of the type A2 neurotoxin gene cluster in Clostridium botulinum. FEMS Microbiol Lett 235:9-16
41. Dong M et al (2003) Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol 162:1293-1303
42. Dong M et al (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312:592-596
43. Dong M et al (2008) Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell 19:5226-5237
44. Dressler D, Benecke R (2004) Autonomic side effects of botulinum toxin type B therapy. Adv Neurol 94:315-320
45. Eisele KH et al (2011) Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon 57:555-565
46. Elias M et al (2011) Evidence that botulinum toxin receptors on epithelial cells and neuronal cells are not identical: implications for development of a non-neurotropic vaccine. J Pharmacol Exp Ther 336:605-612
47. Emsley P et al (2000) The structures of the Hc fragment of tetanus toxin with carbohydrate subunit complexes provide insight into ganglioside binding. J Biol Chem 275:8889-8894
48. Evergren E et al (2007) Intersectin is a negative regulator of dynamin recruitment to the synaptic endocytic zone in the central synapse. J Neurosci 27:379-390
49. Fischer A, Montal M (2013) Molecular dissection of botulinum neurotoxin reveals interdomain chaperone function. Toxicon 5:00033-00030
50. Fotinou C et al (2001) The crystal structure of Tetanus Toxin Hc fragment complexed with a synthetic GT1b analogue suggests cross-linking between ganglioside receptors and the toxin. J Biol Chem 276:3274-3281
51. Fu FN, Sharma SK, Singh BR (1997) A protease-resistant novel hemagglutinin purified from type A Clostridium botulinum. J Prot Chem 17:53-60
52. Fu Z et al (2006) Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate. BioChemistry 45:8903-8911
53. Fu Z et al (2009) Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. BioChemistry 48:5631-5641
54. Fujinaga Y et al (1994) Molecular construction of Clostridium botulinum type C progenitor toxin and its gene organization. Biochem Biophys Res Commun 205:1291-1298
55. Fujinaga Y et al (1997) The haemagglutinin of Clostridium botulinum type C progenitor toxin plays an essential role in binding of toxin to the epithelial cells of guinea pig intestine, leading to the efficient absorption of the toxin. Microbiology 143:3841-3847
56. Fujinaga Y et al (2000) Identification and characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes. FEBS Lett 467:179-183
57. Fujinaga Y et al (2003) Gangliosides that associate with lipid rafts mediate transport of cholera and related toxins from the plasma membrane to endoplasmic reticulum. Mol Biol Cell 14:4783-4793
58. Fujinaga Y et al (2004) Molecular characterization of binding subcomponents of Clostridium botulinum type C progenitor toxin for intestinal epithelial cells and erythrocytes. Microbiology 150:1529-1538
59. Fujinaga Y (2006) Transport of bacterial toxins into target cells: pathways followed by cholera toxin and botulinum progenitor toxin. J Biochem 140:155-160
60. Fujinaga Y et al (2009) A novel function of botulinum toxin-associated proteins: HA proteins disrupt intestinal epithelial barrier to increase toxin absorption. Toxicon 54:583-586
61. Fujinaga Y, Sugawara Y, Matsumura T (2013) Uptake of botulinum neurotoxin in the intestine. Curr Top Microbiol Immunol 364:45-59
62. Fujita R et al (1995) Molecular characterization of two forms of nontoxic-non hemagglutinantinin components of Clostridium botulinum type A progenitor toxins. FEBS Lett 376:41-44
63. Garner CG et al (1993) Time course of distant effects of local injections of botulinum toxin. Mov Disord 8:33-37
64. Gauthier NC et al (2005) Helicobacter pylro VacA cytotoxin: a probe for a clathrin-independent and Cdc42-dependent pinocytic pathway routed to late endosomes. Mol Biol Cell 16:4852-4866
65. Gill DM (1987) Bacterial Toxcins: lethal amounts. In: Laskin AI, Lechevalier HA (eds) Toxins and Enzymes. CRC Press, Cleveland, pp 127-135
66. Girlanda P et al (1992) Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 55:844-845
67. Gracies JM (2004) Physiological effects of botulinum toxin in spasticity. Mov Disord 19(Suppl 8):S120-128
68. Gu S, Jin R (2013) Assembly and function of the botulinum neurotoxin progenitor complex. Curr Top Microbiol Immunol 364:21-44
69. Gu S et al (2012) Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 335:977-981
70. Gumbiner BM (1996) Cell adhesion; the molecular basis of tissue architecture and morphogenesis. Cell 84:345-357
71. Hartsock A, Nelson WJ (2008) Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta 1778:660-669
72. Hasegawa K et al (2007) A novel subunit structure of clostridium botulinum serotype D toxin complex with three extended arms. J Biol Chem 282:24777-24783
73. Hatheway C, McCroskey LM (1987) Examination of feces and serum for diagnosis of infant botulism in 336 patients. J Clin Microbiol 25:2334-2338
74. Hines HB et al (2005) Characterization of botulinum progenitor toxins by mass spectrometry. Appl Environ Microbiol 71:4478-4486
75. Holzer E (1962) Botulism caused by inhalation. Med Klin 41:1735-1740
76. Inoue K et al (1999) Characterization of haemagglutinin activity of Clostridium botulinum type C and D 16S toxins, and one subcomponent of haemagglutinin (HA1). Microbiology 145:2533-2542
77. Inoue K et al (2001) Clostridium botulinum type A haemagglutinin positive progenitor toxin (HA + -PTX) binds to oligosaccharides containing Galb1-4GlcNAc through one subcomponent of haemagglutinin (HA1). Microbiology 147:811-819
78. Inoue K et al (2003) Structural analysis by X-ray crystallography and calorimetry of a haemagglutinin component (HA1) of the progenitor toxin from Clostridium botulinum. Microbiology 149:3361-3370
79. Inui K et al (2010) Involvement of sialic acid in transport of serotype C1 botulinum toxins through rat intestinal epithelial cells. J Vet Med Sci 72:1251-1255
80. Ito H et al (2011) HA-33 facilitates transport of the serotype D botulinum toxin across a rat intestinal epithelial cell monolayer. FEMS Immunol Med Microbiol 61:323-331
81. Jacobson MJ et al (2008) Analysis of neurotoxin cluster genes in Clostridium botulinum strains producing botulinum neurotoxin serotype A subtypes. Appl Environ Microbiol 74:2778-2786
82. Jankovic J, Brin MF (1991) Therapeutic uses of botulinum toxin. N Engl J Med 324:1186-1194
83. Jin Y et al (2009) Disruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins-differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type C. Microbiology 155:35-45
84. Keller JE, Cai F, Neale EA (2004) Uptake of botulinum neurotoxin into cultured neurons. Biochemistry 43:526-532
85. Kerneis S et al (1997) Conversion by Payer's patche lymphocyte of human enterocytes into M cells that transport bacteria. Science 277:949-952
86. Kerneis S et al (2000) Molecular studies of the intestinal mucosal barrier physiopathology using cocultures of epithelial and immune cells: a technical update. Microb Infect 2:1119-1124
87. Kim DY, Oh BM, Paik NJ (2006) Central effect of botulinum toxin type A in humans. Int J Neurosci 116:667-680
88. Kitamura M, Sakaguchi S, Sakaguchi G (1969) Significance of 12S toxin of Clostridium botulinum type E. J Bacteriol 98:1173-1178
89. Kitamura M et al (2005) Different response of the knockout mice lacking b-series gangliosides against botulinum and tetanus toxins. Biochim Biophys Acta 1741:1-3
90. Kobayashi H et al (2003) A botulism case of a 12-year-old girl caused by intestinal colonization of Clostridium botulinum type Ab. Jpn J Infect Dis 56:73-74
91. Kojima S et al (2005) Clostridium botulinum type A progenitor toxin binds to Intestine-407 cells via N-acetyllactosamine moiety. Biochem Biophys Res Commun 331:571-576
92. Kouguchi H et al (2002) In vitro reconstitution of the Clostridium botulinum type D progenitor toxin. J Biol Chem 277:2650-2656
93. Kozaki S et al (1998) Characterization of Clostridium botulinum type B neurotoxin associated with infant botulism in Japan. Infect Immun 66:4811-4816
94. Kumaran D et al (2009) Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J Mol Biol 386:233-245
95. Lacy DB, Stevens RC (1999) Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 291:1091-1104
96. Lacy DB et al (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nature Struct Biol 5:898-902
97. Lalli G et al (2003) The journey of tetanus and botulinum neurotoxins in neurons. Trends Microbiol 11:431-437
98. Lamanna C (1959) The most poisonous poison. Science 130:763-772
99. Lamaze C, Johannes L (2006a) Intracellular trafficking of bacterial and plant toxins. In:Alouf JE, Popoff MR (eds) The Comprehensive sourcebook of bacterial protein toxins, Elsevier-Academic Press, Amsterdam, pp 135-153
100. Lamaze C, Johannes L (2006b) Intracellular trafficking of bacterial and plant protein toxins. In: Alouf JE, Popoff MR (eds) The sourcebook of bacterial protein toxins, Elsevier Academic Press, Amsterdam, pp 135-153
101. Lietzow MA et al (2008) Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis. Protein J 27:420-425
102. Lin G et al (2010) Expression of the Clostridium botulinum A2 neurotoxin gene cluster proteins and characterization of the A2 complex. Appl Environ Microbiol 76:40-47
103. Lindström M, Korkeala H (2006) Laboratory diagnosis of botulism. Clin Microbiol Rev 19:298-314
104. Low PA (2002) Autonomic neuropathies. Curr Opin Neurol 15:605-609
105. Mahmut N et al (2002) Characterization of monoclonal antibodies against haemagglutinin associated with Clostridium botulinum type C neurotoxin. J Med Microbiol 51:286-294
106. Mahrhold S et al (2006) The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 580:2011-2014
107. Maksymowych AB, Simpson LI (2004) Structural features of the botulinum neurotoxin molecule that govern binding and transcytosis across polarized human intestinal epithelial cells. J Pharmacol Exp Ther 210:633-641
108. Maksymowych AB, Simpson LL (1998) Binding and transcytosis of botulinum neurotoxin by polarized human carcinoma cells. J Biol Chem 273:21950-21957
109. Maksymowych AB et al (1999) Pure botulinum neurotoxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade. Infect Immun 67:4708-4712
110. Matsumura T et al (2008) The HA proteins of botulinum toxin disrupt intestinal epithelial intercellular junctions to increase toxin absorption. Cell Microbiol 10:355-364
111. May AJ, Whaler BC (1958) The absorption of Clostridium botulinum type A toxin from the alimentary canal. Br J Exp Path 39:307-316
112. Mayor S, Pagano RE (2007) Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 8:603-612
113. Mayor S, Rao M (2004) Rafts: scale-dependent, active lipid organization at the cell surface. Traffic 5:221-240
114. McClane BA (2006) Clostridium perfringens enterotoxin. In: Alouf JE, Popoff MR (eds) The comprehensive sourcebook of bacterial protein toxins. Elsevier Academic Press, Amsterdam, pp 763-778
115. Middlebrook JL (1986) Cellular mechanism of action of botulism neurotoxin. J Toxicol 5:177-180
116. Middlebrook JL, Franz DR (1997) Botulinum toxins. In: Sidell FR, Takafuji ET, Franz DR (eds) Medical aspects of chemical and biological warfare. The Surgeon General, Washington, DC, pp 643-654
117. Miyata K et al (2009) Expression and stability of the nontoxic component of the botulinum toxin complex. Biochem Biophys Res Commun 384:126-130
118. Moberg LJ, Sugiyama H (1979) Microbial ecological basis of infant botulism as studied with germfree mice. Infect Immun 25:653-657
119. Moberg LJ, Sugiyama H (1980) The rat as an animal model for infant botulism. Infect Immun 29:819-821
120. Montal M, Botulinum N (2010) A Marvel of Protein Design. Annu Rev Biochem 79:591-617
121. Moreno-Lopez B et al (1997) Effects of botulinum neurotoxin type A on abducens motorneurons in the cat: alterations of the discharge pattern. Neuroscience 81:437-455
122. Mostov KE, Verges M, Altschuler Y (2000) Membrane traffic in polarized epithelial cells. Cell Biol 12:483-490
123. Mutoh S et al (2003) Complete subunit structure of the Clostridium botulinum type D complex via intermediate assembly with nontoxic components. Biochemistry 42:10991-10997
124. Nishikawa A et al (2004) The receptor and transporter for internalization of Clostridium botulinum type C progenitor toxin into HT-29 cells. Biochem Biophys Res Commun 319:327-333
125. Nishiki T et al (1996) The high-affinity of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1B/GD1a. FEBS Lett 378:253-257
126. Niwa K et al (2007) Role of nontoxic components of serotype D botulinum toxin complex in permeation through a Caco-2 cell monolayer, a model for intestinal epithelium. FEMS Immunol Med Microbiol 49:346-352
127. Niwa K et al (2010) Sialic acid-dependent binding and transcytosis of serotype D botulinum neurotoxin and toxin complex in rat intestinal epithelial cells. Vet Microbiol 141:312-320
128. Oguma K et al (1999) Structure and function of Clostridium botulinum progenitor toxin. J Toxicol 18:17-34
129. Ohishi I, Sakaguchi G (1980) Oral toxicities of Clostridium botulinum type C and D toxins of different molecular sizes. Infect Immun 28:303-309
130. Ohishi I, Sugii S, Sakaguchi G (1977) Oral toxicites of Clostridium botulinum toxins in response to molecular size. Infect Immun 16:107-109
131. Ouzilou L et al (2002) Poliovirus transcytosis through M-like cells. J Gen Virol 83:2177-2182
132. Park JB, Simpson LL (2003) Inhalation poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect Immun 71:1147-1154
133. Paton JC, Lawrence AJ, Steven IM (1983) Quantities of Clostridium botulinum organisms and toxin in feces and presence of Clostridium botulinum toxin in the serum of an infant with botulism. J Clin Microbiol 17:13-15
134. Petro KA et al (2006) Disruption of lipid rafts enhances activity of botulinum neurotoxin serotype A. Toxicon 48:1033-1045
135. Pickett A (2009) Dysport pharmacological properties and factors that influence toxin action. Toxicon 54:683-689
136. Popoff MR, Geny B (2009) Multifaceted role of Rho, Rac, Cdc42 and Ras in intercellular junctions, lessons from toxins. Biochim Biophys Acta 1788:797-812
137. Popoff MR, Marvaud JC (1999) Structural and genomic features of clostridial neurotoxins. In: Alouf JE, Freer JH (eds) The comprehensive sourcebook of bacterial protein toxins. Academic Press, London, pp 174-201
138. Poulain B, Popoff MR, Molgo J (2008) How do the botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J 1:14-87
139. Predescu SA et al (2003) Intersectin regulates fission and internalization of caveolae in endothelial cells. Mol Biol Cell 14:4997-5010
140. Quinn CP, Minton NP (2001) Clostridial neurotoxins. In: Bahl H, Dürre P (eds) Clostridia, Willey-VCH, Veinheim, pp 211-250
141. Ramachandran R et al (2002) Structural insights into the membrane-anchoring mechanism of a cholesterol-dependent cytolysin. Nat Struct Biol 9:823-827
142. Ravichandran E et al (2006) An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 318:1343-1351
143. Restani L et al (2011) Evidence for Anterograde Transport and Transcytosis of Botulinum Neurotoxin A (BoNT/A). J Neurosci 31:15650-15659
144. Restani L et al (2012) Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog 8:e1003087
145. Restani L et al (2012) Botulinum neurotoxin a impairs neurotransmission following retrograde transynaptic transport. Traffic 13:1083-1089
146. Roche N et al (2008) Undesirable distant effects following botulinum toxin type A injection. Clin Neuropharmacol 31:272-280
147. Roux A et al (2006) GTP-dependent twisting of dynamin implicates constriction and tension in membrane fission. Nature 441:528-531
148. Rummel A et al (2004a) Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J Biol Chem 279:30865-30870
149. Rummel A et al (2004b) The Hcc-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol 51:631-643
150. Rummel A et al (2007) Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc Natl Acad Sci U S A 104:359-364
151. Rummel A et al (2009) Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J Neurochem 110:1942-1954
152. Sabharanjak S et al (2002) GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway. Develop. Cell 2:411-423
153. Sagane Y et al (2000) Characterization of nicking of the nontoxic-nonhemagglutinin components of Clostridium botulinum types C and D progenitor toxin. J Protein Chem 19:575-581
154. Sagane Y et al (2001) Role of C-terminal region, of HA-33 component of botulinum toxin in hemagglutination. Biochem Biophys Res Commun 288:650-657
155. Sakaguchi G (1983) Clostridium botulinum Toxins. Pharmac Ther 19:165-194
156. Sanford DC et al (2010) Inhalational botulism in rhesus macaques exposed to botulinum neurotoxin complex serotypes A1 and B1. Clin Vaccine Immunol 17:1293-1304
157. Sears CL (2001) The toxins of Bacteroides fragilis. Toxicon 39:1737-1746
158. Sears CL, Franco AA, Wu S (2006) Bacteroides fragilis toxins. In: Alouf JE, Popoff MR (eds) The sourcebook of bacterial protein toxins, Elsevier Academic Press, Amsterdam, pp 535-546
159. Sebald M, Saimot G (1973) Le diagnostic biologique du botulisme. Med Mal Inf 3:83-85
160. Sharma DK et al (2003) Glycosphingolipids internalized via caveolar-related endocytosis rapidly merge with the clathrin pathway in early endosomes and form microdomains for recycling. J Biol Chem 278:7564-7572
161. Sharma SK, Fu FN, Singh BR (1999) Molecular properties of a hemagglutinin purified from type A Clostridium botulinum. J Protein Chem 18:29-38
162. Sharma SK, Ramzan MA, Singh BR (2003) Separation of the components of type A botulinum neeurotoxin complex by electrophoresis. Toxicon 41:321-331
163. Sheth AN et al (2008) International outbreak of severe botulism with prolonged toxemia caused by commercial carrot juice. Clin Infect Dis 47:1245-1251
164. Simpson F et al (1999) SH3-domain-containing proteins function at distinct steps in clathrincoated vesicle formation. Nature Cell Biol 1:119-124
165. Simpson LL, Coffield JA, Bakry N (1994) Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins. J Pharmacol Exp Ther 269:256-262
166. Smith LA (2006) Bacterial protein toxins as biological weapons. In: Alouf JE, Popoff MR (eds) The comprehensive sourcebook of bacterial protein toxins. Elsevier Academic Press, Amsterdam, pp 1019-1030
167. Sobel J (2005) Botulism. Clin Infect Dis 41:1167-1173
168. Stenmark P et al (2008) Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog 4:e1000129
169. Sugawara Y et al (2010) Botulinum hemagglutinin disrupts the intercellular epithelial barrier by directly binding E-cadherin. J Cell Biol 189:691-700
170. Sugawara Y, Fujinaga Y (2011) The botulinum toxin complex meets E-cadherin on the way to its destination. Cell Adh Migr 5:34-36
171. Sugii S, Ohishi I, Sakaguchi G (1977a) Correlation between oral toxicity and in vitro stability of Clostridium botulinum type A and B toxins of different molecular sizes. Infect Immun 16:910-914
172. Sugii S, Ohishi I, Sakaguchi G (1977b) Intestinal absorption of botulinum toxins of different molecular sizes in rats. Infect Immun 17:491-496
173. Sugiyama H (1980) Clostridium botulinum neurotoxin. Microbiol Rev 44:419-448
174. Sugiyama H, Mills DC (1978) Intraintestinal toxin in infant mice challenged intragastrically with Clostridium botulinum spores. Infect Immun 21:59-63
175. Sun S et al (2012) Botulinum Neurotoxins B and E Translocate at Different Rates and Exhibit Divergent Responses to GT1b and Low pH. Biochemistry 52:5655-5662
176. Swaminathan S, Eswaramoorthy S (2000) Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nature Struct Biol 7:693-699
177. Tacket CO, Rogawski MA (1989) Botulism. In: Simpson LL (ed) Botulinum neurotoxin and Tetanus toxin Academic Press, San Diego, pp 351-378
178. Takei K, Yoshida Y, Yamada H (2005) Regulatory mechanisms of dynamin-dependent endocytosis. J Biochem (Tokyo) 137:243-247
179. Taysse L et al (2005) Induction of acute lung injury after intranasal administration of toxin botulinum A complex. Toxicol Pathol 33:336-342
180. Umland TC et al (1997) The structure of the receptor binding fragment Hc of tetanus neurotoxin. Nature Struct 4:788-792
181. Uotsu N et al (2005) Cell internalization and traffic pathway of Clostridium botulinum type C neurotoxin in HT-29 cells. Biochim Biophys Acta 1763:120-128
182. Verderio C et al (2007) Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic 8:142-153
183. Wells CL, Sugiyama H, Bland SE (1982) Resistance of mice with limited intestinal flora to enteric colonization by Clostridium botulinum. J Infect Dis 146:791-796
184. Wiegand H, Erdmann G, Wellhoner HH (1976) 125I-labelled botulinum A neurotoxin:pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 292:161-165
185. Wohlfarth K et al (2001) Remote F-wave changes after local botulinum toxin application. Clin Neurophysiol 112:636-640
186. Wohlfarth K et al (2009) Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin 25:1573-1584
187. Yoneyama T et al (2008) Clostridium botulinum serotype D neurotoxin and toxin complex bind to bovine aortic endothelial cells via sialic acid. FEMS Immunol Med Microbiol 54:290-298
188. Yowler BC, Kensinger RD, Schengrund CL (2002) Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J Biol Chem 277:32815-32819